The Role of IL-17A in Axial Spondyloarthritis and Psoriatic Arthritis: Recent Advances and Controversies

Ann Rheum Dis. 2019 Sep;78(9):1167-1178. doi: 10.1136/annrheumdis-2019-215356. Epub 2019 Jul 5.


Although the pathogenic mechanisms underlying axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are not fully elucidated, several lines of evidence suggest that immune responses mediated by interleukin 17A (IL-17A) play a pivotal role in both diseases. This is best highlighted by the significant clinical efficacy shown with inhibitors of IL-17A in treating axSpA and PsA. Nevertheless, a number of knowledge gaps exist regarding the role of IL-17A in the pathophysiology of spondyloarthritis in man, including its cellular origin, its precise role in discrete disease processes such enthesitis, bone erosion, and bone formation, and the reasons for the discrepant responses to IL-17A inhibition observed in certain other spondyloarthritis manifestations. In this review, we focus on the latest data from studies investigating the role of IL-17A in ankylosing spondylitis (AS) and PsA that build on existing and emerging scientific knowledge in the field. Key remaining research questions are also highlighted to guide future research.

Keywords: ankylosing spondylitis; inflammation; psoriatic arthritis; spondyloarthritis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Arthritis, Psoriatic / drug therapy
  • Arthritis, Psoriatic / metabolism*
  • Biomarkers / metabolism
  • Humans
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-17 / physiology*
  • Spondylarthritis / drug therapy
  • Spondylarthritis / metabolism*


  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • IL17A protein, human
  • Interleukin-17
  • secukinumab